Introduction
============

Triple-negative breast cancer (TNBC) accounts for about 10%--20% of newly diagnosed breast cancer. It is characterized by the negative expression of human EGFR-2, estrogen receptor, and progesterone receptor.[@b1-cmar-10-4891] Female patients with TNBC were commonly relapsed and progressed. The peak recurrence rate was observed from the third year to the fifth year after diagnosis. TNBC is featured by intrinsic aggressive tumor pathology, such as high levels of histological grade, proliferation, TP53 mutations, and mitotic index, which leads to larger tumor sizes and poorer clinical outcomes.[@b2-cmar-10-4891],[@b3-cmar-10-4891]

Therefore, it is particularly important to predict the prognosis of these patients. Currently, prognostic factors for patients with TNBC mainly include histological grade, tumor size, and lymph node status. Several novel prognostic factors such as cfDNA, lymphocyte infiltration, and circulating tumor cells have been identified in recent years.[@b4-cmar-10-4891]--[@b7-cmar-10-4891] The clinical application of these markers is limited because the cost of detecting these factors is high and there is a lack of evidence regarding their prognostic value.

Accumulating evidence indicated that systemic inflammation can be a marker for predicting the prognosis of patients with a variety of cancers, for example, breast cancer.[@b8-cmar-10-4891]--[@b20-cmar-10-4891] Systemic inflammation can be monitored using hematologic or biochemical markers, such as elevated C-reactive protein, leukocyte, neutrophil, platelet cell counts, and hypoalbuminemia. The leukocyte count minus neutrophil count was equivalent to the count of lymphocyte. The derived neutrophil-to-lymphocyte ratio (dNLR) was defined as neutrophil count/(leukocyte count -- neutrophil count). Therefore, the high dNLR may be due to the increased neutrophil count or decreased lymphocyte count. Several other studies have used the dNLR (neutrophil/leukocyte -- neutrophil) as a prognostic indicator for cancers; their results have shown that elevated dNLR was related to poor prognosis of patients with lung cancer, renal cell carcinoma, pancreatic cancer, gastric cancer, urothelial carcinoma, hepatocellular carcinoma, colorectal cancer, and lymphoma.[@b21-cmar-10-4891]--[@b27-cmar-10-4891] The evidence for a prognostic role of dNLR in breast cancer is rare and controversial. Thus, we hoped to explore the prognostic role of dNLR in surgical TNBC patients.

Methods
=======

A total of 281 patients diagnosed with surgical TNBC in The First Affiliated Hospital of The University of Science and Technology of China, from February 2005 to March 2015, were retrospectively included. We included patients with histological confirmation of TNBC; data for differential blood counts were collected prior to anticancer treatment. We excluded patients with inflammatory disease, immune disease, coronary artery disease, and hematological diseases; suffering from an infectious disease within 1 month of enrollment; using anti-inflammatory or immunosuppressive drugs (steroids, azathioprine, antilymphocyte globulin, and rapamycin) prior to enrollment; and with metastatic or inflammatory breast cancer. The ethics committee of The First Affiliated Hospital of The University of Science and Technology of China approved this study, and the written informed consent was not required for individual patient because this study was retrospective and data were anonymous.

All patients underwent radical mastectomy or breast-conserving surgery. Patients who underwent neoadjuvant or adjuvant chemotherapy received anthracyclines, cyclophos-phamide, and paclitaxel. There were 202 (71.9%) patients who received chemotherapy with anthracyclines+cycloph osphamide+paclitaxel, whereas 79 (28.1%) patients who received anthracyclines+paclitaxel. The radiation dose of postoperative radiotherapy was 50--60 Gy/25--30 fractions. Data for leukocyte count, neutrophil count, lymphocyte count, patients' age, tumor size, lymph node metastasis, lymphovascular invasion, histological grade, proliferative index (Ki-67), and antitumor therapy (eg, surgery, radiotherapy, chemotherapy, and targeted therapy) were collected. The dNLR was defined as neutrophil count/(leukocyte count -- neutrophil count). We collected the dNLR 1 week before surgery or neoadjuvant chemotherapy.

The follow-up was regularly conducted every 3 months after surgery until death or discontinuation from the study. Ultrasound imaging, computed tomography, MRI, and positron emission computed tomography were used to assess disease status. The contents of follow-up included the extent of disease progression, death, and discontinuation. The deadline for follow-up was March 10, 2018. Overall survival (OS) is defined as the time from pathological diagnosis to death or lost follow-up. Disease-free survival (DFS) time is defined as the time from operation to the first instance of disease recurrence, metastasis, lost follow-up, or death.

Statistical analysis
--------------------

We used the Cox regression model for multivariate analysis to identify independent factors for prognosis in TNBC patients. The OS and DFS were evaluated by the Kaplan--Meier method. The log-rank test was used for the comparison of differences in survival between patients from the two groups. Using the receiver operating characteristic curve (ROC) analysis ([Figure S1](#SD1-cmar-10-4891){ref-type="supplementary-material"}), dNLR (2.6) with the highest area under the curve was selected as the cutoff value between long and short OS. Patients were divided into low dNLR group and high dNLR group by the cutoff point of dNLR. *P*\<0.05 was accepted as the statistically significant difference. The SPSS22.0 software (IBM Corporation, Armonk, NY, USA) was used for data analysis.

Results
=======

[Table 1](#t1-cmar-10-4891){ref-type="table"} shows the clinicopathological parameters for patients. A total of 281 TNBC patients were included in the present study. According to the American Joint Committee on Cancer staging system, 39, 150, and 92 cases of patients were at stage I, II, and III of disease, respectively. Among whom, 39 patients had lymphovascular invasion. Forty-six patients received breast-conserving surgery, and 235 patients underwent modified radical mastectomy. There were 34, 147, and 100 patients with histopathological grade I, II, and III, respectively. One hundred nine patients had low dNLR, and 172 patients had high dNLR. The median dura tion of follow-up was 67 months (16--148 months). At the end of follow-up, 196 cases were died, nine cases were lost for follow-up, and 235 patients had recurrent or metastatic cancer. The median DFS and OS were 23 and 61.1 months, respectively.

The median DFS of low and high dNLR TNBC patients was 28.9 and 15.1 months, respectively (*P*\<0.001, [Figure 1](#f1-cmar-10-4891){ref-type="fig"}), whereas the median OS of low and high dNLR patients was 71.2 and 42.3 months, respectively (*P*\<0.001; [Figure 2](#f2-cmar-10-4891){ref-type="fig"}). For patients aged ≤50 years, the DFS and OS were higher in low dNLR patients than in high dNLR patients (25.8 vs 15.0 months, *P*\<0.001; 68.3 vs 44.0 months, *P*=0.006; respectively, [Figures 3](#f3-cmar-10-4891){ref-type="fig"} and [4](#f4-cmar-10-4891){ref-type="fig"}). For patients with invasive ductal carcinoma, the median DFS of low and high dNLR patients was 29.3 and 14.2 months, respectively (*P*\<0.001; [Figure 5](#f5-cmar-10-4891){ref-type="fig"}), whereas the median OS of low and high dNLR patients was 71.6 and 44 months, respectively (*P*=0.002; [Figure 6](#f6-cmar-10-4891){ref-type="fig"}).

Univariate analysis showed that higher tumor stage, lymphovascular invasion, histological grade, lymph node status, and dNLR were related to poor DFS (*P*\<0.05, [Table 2](#t2-cmar-10-4891){ref-type="table"}). In addition to dNLR, we included confounding factors (age, type of surgery, tumor stage, lymphovascular invasion, histological grade, lymph node status, adjuvant radiotherapy, and chemotherapy) in multivariate analysis. It was showed in the multivariate analysis that increased dNLR was an independent predictor of poor DFS (HR=1.90, 95% CI: 1.52--2.46, *P*=0.007; [Table 2](#t2-cmar-10-4891){ref-type="table"}). High dNLR, tumor stage, lymphovascular invasion, histological grade, and lymph node status predicted shorter OS (*P*\<0.05, [Table 3](#t3-cmar-10-4891){ref-type="table"}). Also, increased dNLR was showed an independent predictor of poor OS in multivariate analysis (HR=2.56, 95% CI: 1.69--3.58, *P*=0.001; [Table 3](#t3-cmar-10-4891){ref-type="table"}). For the clinicopathological parameters, we also found that histological grade and tumor stage were independently related to survival of TNBC patients (*P*\<0.05, [Tables 2](#t2-cmar-10-4891){ref-type="table"} and [3](#t3-cmar-10-4891){ref-type="table"}).

Discussion
==========

Few studies have reported the correlation between dNLR and the prognosis of TNBC patients, particularly in the Chinese population. To our knowledge, our study included the largest sample size compared with any other studies exploring the value of dNLR in predicting the prognosis of Chinese TNBC patients.

During inflammatory responses, the circulating cytokines and chemokines were released from the increased number of neutrophil and platelet counts. The counts of lymphocyte were declined.[@b28-cmar-10-4891] Neutrophils play important roles in tumor expansion, angiogenesis, and metastasis.[@b29-cmar-10-4891] Previous studies have demonstrated the association of inflammatory responses with the development, progression, metastasis, and relapse of cancer.[@b30-cmar-10-4891] Notably, tumor lymphocyte infiltration appeared to be related to tumor prognosis.[@b6-cmar-10-4891],[@b7-cmar-10-4891],[@b31-cmar-10-4891]Activation status of T cells was positively associated with the OS in patients with breast cancer.[@b32-cmar-10-4891],[@b33-cmar-10-4891] Additionally, it has shown that status of tumor-infiltrating lymphocyte that expressing the pro grammed cell death 1-ligand 1 was an favorable independent predictor of prognosis for patients with inflammatory breast cancer, suggesting that immune checkpoint immunotherapy should be explored and correlated with prognosis in these patients.[@b34-cmar-10-4891]

Studies have demonstrated that high dNLR was related to the poor prognosis of multiple cancers.[@b25-cmar-10-4891],[@b35-cmar-10-4891]--[@b39-cmar-10-4891] Among these, a few studies have explored the role of dNLR in breast cancer, but the results were inconsistency. Proctor et al[@b40-cmar-10-4891] found that increased levels of dNLR were related to poor prognosis for patients with breast cancer; however, they did not take into account the clinical stage, tumor histopathological grade, hormone receptor status, and previous treatments of patients, thus making it impossible to assess whether dNLR was associated with prognosis after adjusting other factors. In another study, Dirican et al[@b37-cmar-10-4891] analyzed 1,527 cases of breast cancer. The results showed a significant association between increased dNLR and the DFS and OS; however, their multivariate analysis did not show an independent prognostic value of dNLR for breast cancer.

In our study, we collected the dNLR 1 week before surgery or neoadjuvant chemotherapy to avoid treatments inducing change in dNLR. Our study provided evidence that dNLR is significantly related to the OS and DFS in TNBC patients. This correlation is still significant after adjusting the patients' age, lymph node metastasis, tumor size, and histopathological grading. Our results suggested that elevated dNLR is independently correlated with high mortality, suggesting that increased dNLR is potentially used as an independent predictor for prognosis in TNBC patients. By releasing ROS, tumor inflammatory mediators, arginase, nitric oxide, and remodeling the extracellular matrix, neutrophils promote tumor development,[@b41-cmar-10-4891],[@b42-cmar-10-4891] which may explain our findings. In our study, patients with breast cancer underwent routine blood tests prior to first-line treatment. Consequently, the assessment of dNLR was readily available without any additional costs. Therefore, preoperative dNLR may be used as an indicator to predict the survival of TNBC patients.

However, our study also had some shortcomings. First, there was no external validation used in this study. Second, bias of selecting cases was inevitable in the single-center retrospective study. Despite these limitations, our study still provided strong evidence for a role of dNLR in predicting the prognosis of TNBC patients.

Conclusion
==========

This study showed that dNLR may be an independent factor for predicting the prognosis of TNBC patients. Patients with high dNLR (≥2.6) may have worse survival and may be selected for aggressive therapies, such as high-dose chemotherapy and radiotherapy. Prospective studies with large sample size are still necessary for confirming the prognostic value of dNLR.

Supplementary material
======================

###### 

ROC curve to distinguish long and short OS by dNLR.

**Abbreviations:** dNLR, derived neutrophil-to-lymphocyte ratio; OS, overall survival; ROC, receiver operating characteristic curve; AUC, area under the curve.
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![Overall survival of TNBC patients aged ≤50 years divided by dNLR.\
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![The disease-free survival in TNBC patients with invasive ductal carcinoma divided by dNLR.\
**Abbreviations:** dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.](cmar-10-4891Fig5){#f5-cmar-10-4891}

![The overall survival in TNBC patients with invasive ductal carcinoma divided by dNLR.\
**Abbreviations:** dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.](cmar-10-4891Fig6){#f6-cmar-10-4891}

###### 

Clinicopathological parameters of 281 patients with triple-negative breast cancer

  Parameters                    N=281   \%
  ----------------------------- ------- ----
                                        
  Age (years)                           
   ≤50                          201     72
   \>50                         80      28
  Type of surgery                       
   Breast-conserving surgery    46      16
   Radical mastectomy           235     84
  Tumor stage                           
   pT1                          59      21
   pT2                          167     59
   pT3                          50      18
   pT4                          5       2
  Tumor histology                       
   Invasive ductal carcinoma    223     79
   Invasive lobular carcinoma   55      20
   Others                       3       1
  Lymphovascular invasion               
   Yes                          39      14
   No                           242     86
  Histological grade                    
   I--II                        181     64
   III                          100     36
  Ki-67                                 
   ≥30%                         121     43
   \<30%                        160     57
  Lymph node status                     
   pN0                          118     42
   pN1                          96      34
   pN2                          41      15
   pN3                          26      9
  AJCC stage                            
   I                            39      14
   II                           150     54
   III                          92      33
  Adjuvant radiotherapy                 
   Yes                          180     64
   No                           101     36
  Chemotherapy                          
   Neoadjuvant chemotherapy     59      21
   Adjuvant chemotherapy        222     79
  dNLR                                  
   ≥2.6                         109     39
   \<2.6                        172     61

**Abbreviations:** AJCC, American Joint Committee on Cancer; dNLR, derived neutrophil-to-lymphocyte ratio.

###### 

Cox analysis for disease-free survival in 281 patients with triple-negative breast cancer

  Variables                                          Univariate analysis   Multivariate analysis                                 
  -------------------------------------------------- --------------------- ----------------------- --------- ------ ------------ -------
                                                                                                                                 
  Age (years)                                                                                                                    
   \>50 vs ≤50                                       0.69                  0.56--1.09              0.196     0.69   0.51--1.18   0.105
  Type of surgery                                                                                                                
   Radical mastectomy vs breast conserving surgery   1.05                  0.91--1.12              0.244     0.92   0.84--1.24   0.379
  Tumor stage                                                                                                                    
   T2--4 vs T1                                       1.69                  1.16--2.59              0.006     1.50   1.31--2.49   0.015
  Lymphovascular invasion                                                                                                        
   Yes vs no                                         1.24                  1.09--1.76              0.021     1.01   0.92--1.26   0.152
  Histological grade                                                                                                             
   III vs I--II                                      2.31                  1.92--3.16              \<0.001   2.01   1.35--2.59   0.011
  Lymph node status                                                                                                              
   Yes vs no                                         1.94                  1.46--2.38              0.004     1.19   1.16--1.86   0.059
  Adjuvant radiotherapy                                                                                                          
   Yes vs no                                         0.77                  0.69--1.12              0.587     0.72   0.64--1.07   0.659
  Chemotherapy                                                                                                                   
   Neoadjuvant vs adjuvant                           0.84                  0.72--1.15              0.489     0.77   0.69--1.12   0.575
  dNLR                                                                                                                           
   ≥2.6 vs \<2.6                                     2.39                  1.85--2.59              \<0.001   1.90   1.52--2.46   0.007

**Abbreviation:** dNLR, derived neutrophil-to-lymphocyte ratio.

###### 

Cox analysis for overall survival in 281 patients with triple-negative breast cancer

  Variables                                          Univariate analysis   Multivariate analysis                                 
  -------------------------------------------------- --------------------- ----------------------- --------- ------ ------------ -------
                                                                                                                                 
  Age (years)                                                                                                                    
   \>50 vs ≤50                                       0.82                  0.62--1.15              0.354     0.77   0.51--1.26   0.325
  Type of surgery                                                                                                                
   Radical mastectomy vs breast conserving surgery   1.10                  0.82--1.31              0.292     0.98   0.79--1.06   0.453
  Tumor stage                                                                                                                    
   T2--4 vs T1                                       2.43                  1.79--3.26              \<0.001   1.78   1.31--2.84   0.002
  Lymphovascular invasion                                                                                                        
   Yes vs no                                         1.50                  1.18--1.86              0.017     1.31   1.07--1.62   0.047
  Histological grade                                                                                                             
   III vs I--II                                      3.12                  2.62--3.51              \<0.001   2.30   1.75--2.84   0.004
  Lymph node status                                                                                                              
   Yes vs no                                         2.52                  1.76--3.15              0.002     1.86   1.46--2.54   0.018
  Adjuvant radiotherapy                                                                                                          
   Yes vs no                                         0.88                  0.65--1.12              0.837     0.80   0.62--1.08   0.875
  Chemotherapy                                                                                                                   
   Neoadjuvant vs adjuvant                           0.92                  0.81--1.16              0.860     0.83   0.68--1.12   0.926
  dNLR                                                                                                                           
   ≥2.6 vs \<2.6                                     3.13                  1.86--4.26              \<0.001   2.56   1.69--3.58   0.001

**Abbreviation:** dNLR, derived neutrophil-to-lymphocyte ratio.
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